hrp0084p3-944 | GH & IGF | ESPE2015

The Impact of GH Therapy in Noonan Syndrome Children with Identified Mutations in RAS/MAPK Pathway

Malaquias Alexsandra , Moraes Michelle , Funari Mariana , Pereira Alexandre , Bertola Debora , Jorge Alexander

Objective: To evaluate the response to recombinant human GH (rhGH) treatment in NS children with short stature and previously identified mutations in the RAS/MAPK pathway genes.Methods: 23 patients with NS (17 males; 19 PTPN11, 3 RAF1 e 1 SHOC2) were daily treated with rhGH (mean rhGH dose of 47 μg/kg per day). The main outcome measures were 1st year growth velocity, change in height SDS (Noonan syndrome specifi...

hrp0089fc15.4 | Growth and Syndromes | ESPE2018

The Metabolic Profile Associated with RASopathies

Noronha Renata , Homma Thais , Moraes Michelle , Albuquerque Edoarda , Funari Mariana , Pereira Alexandre , Villares Sandra , Bertola Debora , Jorge Alexander , Malaquias Alexsandra

Background: Noonan syndrome (NS) is a frequent autosomal dominant disorder characterized by facial dysmorphisms, heart defects, short stature and learning disabilities. It is caused by mutations in genes within the RAS/MAPK signaling pathway, thus called RASopathies. The RAS/MAPK pathway can also impact the signal transduction of hormones involved in body weight, carbohydrate, and lipid metabolism features scarcely studied only in animal models. This study aimed to describe me...

hrp0092fc11.5 | Pituitary, Neuroendocrinology and Puberty Session 2 | ESPE2019

Survival, Endocrine Disorders and Quality of Life in 135 Children with Craniopharyngioma After Surgical or Combined Treatment

Mazerkina Nadia , Savateev Alexandre , Gorelyshev Sergey , Trunin Yuri , Golanov Andrey , Kutin Maxim , Kalinin Pavel , Konovalov Alexandre

Patients and Methods: We analyzed 135 primary operated craniopharyngioma (CP) patients and 75 CP patients, received radiotherapy/radiosurgery in 2005-2012. Neurologic, endocrine, visual functions, quality of life (QofL) and neuroimaging data before and after treatment were assessed.Patients were divided in 2 groups according to CP location: 48,5% endosellar (ESCP), and 51,5% suprasellar (SSCP). Surgical treatment included tumor e...

hrp0082p1-d2-9 | Adrenals & HP Axis | ESPE2014

Mast Cells in Human Adrenal Gland During Fetal Development

Naccache Alexandre , Duparc Celine , Louiset Estelle , Lefebvre Herve , Castanet Mireille

Background: We previously found that mast cells are present in the human adult adrenal gland with a possible role in the regulation of aldosterone secretion in both physiological conditions and aldosterone-producing adrenocortical adenomas responsible for primary hyperaldosteronism.Objective and Hypotheses: The aim of the present study was to investigate the presence of mast cells in the human fetal adrenal gland, and to provide arguments in favor of the...

hrp0084p3-1044 | Growth | ESPE2015

Value of Alkaline Phosphatase Assay in Short Stature Exploration

Naccache Alexandre , Gayet Claire , Wieliczko Marie Claire , Castanet Mireille

Background: Short stature is a common reason for pediatric endocrinologist consultation, but in many cases, no cause can be identified. Childhood hypophosphatasia has widely variable clinical features from short stature to low bone mineral density with skeletal deformities, and the place of serum alkaline phosphatase (ALP) activity assay could be raised as etiological exploration is not consensualObjective and hypotheses: The aim of our study was to eval...

hrp0097rfc2.3 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

High incidence of Chiari type I anomalies on MRI in young patients with X-linked hypophosphatemic rickets (XLHR)

Rothenbuhler Anya , Parpaleix Alexandre , Debza Yahya , Adamsbaum Catherine , Linglart Agnès , Ertl Diana-Alexandra , Di Rocco Federico

Background: X-linked hypophosphatemic rickets (XLHR) represents the most common form of genetic hypophosphatemia. Even though skull and cranio-vertebral anomalies of potential neurosurgical interest are observed in children with XLHR, their actual incidence and characteristics are not well established. We aimed to analyze the incidence of Chiari type I anomalies in children with XLHRMethods and materials: Our retrospecti...

hrp0095p2-276 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

The challenge of gender identity due to 5α-reductase deficiency- a case report

Herrmann Gloria , Bauer Agnes , Winner Kay , Kapapa Melanie , Stoll Elvira , Serra Alexandre , Wabitsch Martin

The 5α-reductase deficiency type 2 is a rare autosomal recessive 46,XY disorder of sexual development (DSD), presenting with a wide clinical spectrum ranging from a male phenotype with hypospadias to a female phenotype with wolffian structures. Here we report about the clinical, hormonal and molecular characterization of two siblings with a mutation in the SRD5A2 gene, as well as the challenge of gender identity and the importance of psychosocial care. The older sibling ...

hrp0089p1-p013 | Adrenals and HPA Axis P1 | ESPE2018

Role of Mast Cells in the Establishment of the Mineralocorticoid Pathway in the Developing Mouse

Naccache Alexandre , Louiset Estelle , Lamaziere Antonin , Thomas Michael , Arabo Arnaud , Lefebvre Herve , Castanet Mireille

Mast cells are known to control mineralocorticoid synthesis and secretion in human normal adrenal gland and aldosterone-producing adenomas through release of serotonin. We recently detected these immune cells in human fetal adrenal from 18 weeks of gestation in the subcapsular layer, in correlation with the expression of steroidogenic enzymes required for aldosterone biosynthesis. This observation suggests the implication of mast cells in the mineralocorticoid synthesizing pat...

hrp0097p1-153 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Precocious puberty: a new score to assist therapeutic management

Clemenceau Claire , Cuny Ariane , Feray Dagmara , Gayet Claire , Naccache Alexandre , Fraissinet François , Castanet Mireille

Context: Premature breast enlargement before the age of 8 in girls is caused by a broad spectrum from premature thelarche to central precocious puberty. Treatment with GnRH analogues aim to delay either early onset of menstruation with its psychological consequences and/or early epiphyseal fusion. The Indication of treatment is a challenge classically based on the result of the luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test.<p class="ab...

hrp0084p3-1143 | Puberty | ESPE2015

Premature Adrenarche is Associated to Precocious Thelarche but not to Precocious Gonadarche or Pubarche in Chilean Adolescents

Pereira Ana , Corvalan Camila , Mericq Veronica

Background: Premature adrenarche (PA) has been associated to increased metabolic risk. Areas of controversy regarding associated co-morbidities are precocious pubarche, PCOS and lower birth weight, which may depend on ethnic background.Objective and hypotheses: To describe the risk of precocious thelarche (PT, <8 years), pubarche (PP, <8 years F, <9 years M) and gonadarche (PG, <9 years) in children with premature adrenarche.<p class=...